Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

An assessment of the in vitro inhibition of cytochrome P450 enzymes (CYP), UDP-glucuronsyltransferases (UGT) and transporters by phosphodiester- or phosphorothioate-linked oligonucleotides.

Kazmi F, Yerino P, McCoy C, Parkinson A, Buckley DB, Ogilvie BW.

Drug Metab Dispos. 2018 May 7. pii: dmd.118.081729. doi: 10.1124/dmd.118.081729. [Epub ahead of print]

PMID:
29735754
2.
3.
4.

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.

Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A.

Drug Metab Dispos. 2011 Nov;39(11):2020-33. doi: 10.1124/dmd.111.041293. Epub 2011 Jul 27.

5.

An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes.

Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, Ogilvie BW.

Drug Metab Dispos. 2011 Aug;39(8):1370-87. doi: 10.1124/dmd.111.038596. Epub 2011 Apr 27.

7.

The distribution, metabolism, and elimination of clofarabine in rats.

Bonate PL, Arthaud L, Stuhler J, Yerino P, Press RJ, Rose JQ.

Drug Metab Dispos. 2005 Jun;33(6):739-48. Epub 2005 Mar 2.

Supplemental Content

Loading ...
Support Center